SRR8613747
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.410
- MITOTIC_SPINDLE+0.350
- TNFA_SIGNALING_VIA_NFKB+0.340
- MYC_TARGETS_V1+0.280
- UV_RESPONSE_DN+0.250
- MYC_TARGETS_V2+0.240
- TGF_BETA_SIGNALING+0.240
- ANGIOGENESIS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.280
- BILE_ACID_METABOLISM-0.270
- KRAS_SIGNALING_DN-0.250
- ESTROGEN_RESPONSE_LATE-0.200
- XENOBIOTIC_METABOLISM-0.190
- APICAL_SURFACE-0.180
- CHOLESTEROL_HOMEOSTASIS-0.160
- P53_PATHWAY-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613735 | — | E | 0.850 |
| 2 | SRR5088888 | — | — | 0.792 |
| 3 | MNG289 | — | — | 0.760 |
| 4 | TCGA-D8-A27F-01A-11R-A16F-07 | — | E | 0.760 |
| 5 | 3e94d9d5-8c59-4366-babb-193bdc57d661 | — | — | 0.759 |
| 6 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.755 |
| 7 | d4cdfd13-829c-4f29-984b-5a8897437e3e | — | — | 0.735 |
| 8 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.722 |
| 9 | SRR8942947 | — | — | 0.722 |
| 10 | SRR934900 | — | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |